Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies
about
sameAs
Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathwaysPathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body diseaseProteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson diseasePhosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's diseaseLoss of Grainy head-like 1 is associated with disruption of the epidermal barrier and squamous cell carcinoma of the skinA random set scoring model for prioritization of disease candidate genes using protein complexes and data-mining of GeneRIF, OMIM and PubMed records.Effects of gender on nigral gene expression and parkinson disease.Substrate specificity of human kallikreins 1 and 6 determined by phage display.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's diseaseKallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.Correlation between KLK6 expression and the clinicopathological features of glioma.Accumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1.Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death.The many faces of α-synuclein: from structure and toxicity to therapeutic target.Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coliRole of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.The Interplay between Alpha-Synuclein Clearance and SpreadingThe tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy.Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.Cerebrospinal fluid proteome of patients with acute Lyme diseaseLentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.Promises and challenges in developing RNAi as a research tool and therapy for neurodegenerative diseases.Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.Functional roles of human kallikrein-related peptidases.Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells.Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species.The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6).α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.α-Synuclein and protein degradation systems: a reciprocal relationship.Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like PropagationUnleashing the therapeutic potential of human kallikrein-related serine proteases.Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma.The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review.Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.
P2860
Q26779424-855B622B-13DC-4AC3-BF26-FB61C504CA32Q26853610-C3B993F9-0D8D-4F37-9363-00A4ADA0AF73Q27005843-D45BFB07-290D-4C03-B314-EA9AB976963DQ27316174-8D791AB0-27EA-48A3-AB10-A6104F6DBF93Q27321159-6955262B-2037-49AC-90E9-16864DDDD0BDQ30855078-1A83072E-159E-43A9-87D7-4DAC87F52569Q33281319-A4DEEE0A-1B70-4CC6-B0AD-6FA0E36AF653Q33325124-E4CDB2E0-61AA-4DC7-A36E-2A9232D14E35Q33731321-18593603-AD15-40AB-A8DA-752BC9B215E1Q33760744-8F179786-B8DE-44D7-AB2C-E0C43397C4B4Q33898347-A0BE2B13-D711-4E93-AAEE-0072E694FACEQ33898352-3809E3DD-B534-4649-9143-A8AAF2F07FC8Q33947949-210A7170-41A2-456B-8029-EAAFAEA5A4B7Q34087004-E28CF8F1-2053-4C25-9299-A5AA4EE509C8Q34226804-6594E95B-7E74-4042-A402-8F347940FB41Q34739881-B28CF643-8579-414A-9512-6D0202F9C389Q34800137-DDF19B6E-E94A-4E73-B35C-80894CD6D49EQ34972009-DD3E4440-CBEB-45A6-AC99-0F2C5317B645Q35233762-F0768979-BDA7-4C14-A69B-293B8326148BQ35510197-9BC19AF0-AFBF-48B9-BCED-59201FEEDC93Q35833984-6936234E-2514-4879-A6B4-0CF58446D5B9Q35861497-14118C1D-3902-49EB-8B4C-B5614290DAABQ36086721-CD1E0B37-656C-4AF4-BB94-F86B89B09BCAQ36127050-A7BBA763-9E24-490D-A075-D761C1F9F150Q36301174-0A583CA4-99AD-47F5-B36C-2B6E196E8E81Q36512589-67F9E024-F100-4809-9221-E08C71C0B79AQ36565686-B9E46E27-15CF-49BB-B7C4-814515F267E6Q37213687-5E1F2C81-5D06-4B5E-9785-EB7595DBEFA5Q37612613-1C2BDEEF-0F9F-4882-9ED0-A5B6F3386DFAQ37633571-12DE86E0-5DEE-423C-B0B7-84A62D2F72CBQ37697810-0C50ED68-FF3E-4ABC-9375-3FC2CE4419EAQ37716380-A9CF7BA5-2406-4C3C-A2BE-68CA5982A208Q37952006-B9EF8853-0264-40A7-A03A-3A68FEAA7A42Q38038123-DA072D87-558F-4F2B-80A1-8E4CD166C1B5Q38039881-673BE1AF-9586-4D78-818D-401AB6856DEAQ38303579-F7DCFA9D-9EB7-4021-BB2E-B083D7BFE141Q38362486-5E54764E-DF16-4BCF-9B08-B7CAA4AC7FADQ38429421-FC08F24A-AC4F-42AD-B9AC-7D6EAAE22896Q38582520-CC63FE2E-B9C2-4764-AB6B-590341352072Q38652662-4D9BB47B-6CE5-4421-BC72-DD07000FC1C3
P2860
Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@ast
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@en
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@nl
type
label
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@ast
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@en
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@nl
prefLabel
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@ast
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@en
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@nl
P2093
P356
P1476
Alpha-synuclein degradation by ...... hogenesis of synucleinopathies
@en
P2093
Ichiro Kanazawa
Mieko Maruyama
Nobuyuki Nukina
Shoji Tsuji
Takumi Akagi
Tsutomu Hashikawa
P304
P356
10.1093/HMG/DDG283
P407
P577
2003-10-15T00:00:00Z